FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018104037> ?p ?o ?g. }

• W2018104037 endingPage "74" @default.
• W2018104037 startingPage "65" @default.
• W2018104037 abstract "Endogenous cannabinoid ligands and cannabinoid CB1 receptor agonists have been shown to exert potent anticonvulsant effects in various experimental models of epilepsy. The purpose of this study was to determine the effects of arachidonyl-2′-chloroethylamide (ACEA; N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide, a highly selective cannabinoid CB1 receptor agonist) on the threshold for electroconvulsions and the anticonvulsant activity of valproate in the maximal electroshock-induced seizures in mice. To inhibit the rapid metabolic degradation of ACEA by the fatty-acid amide hydrolase, phenylmethylsulfonyl fluoride (PMSF) was used at a constant ineffective dose of 30 mg/kg (i.p.). Moreover, the effects of ACEA and PMSF on the acute adverse-effect profile of valproate were determined in the chimney test. Additionally, the adverse-effect potentials of combination of ACEA, PMSF with valproate were examined in the step-through passive avoidance task (long-term memory) and grip-strength test (neuromuscular strength). To ascertain any pharmacokinetic contribution of ACEA and PMSF to the observed interaction between tested drugs, both free (non-protein bound) plasma and total brain concentrations of valproate were estimated. Results indicated that ACEA (5 and 7.5 mg/kg; i.p.) combined with PMSF increased significantly (P < 0.001) the electroconvulsive threshold in mice. ACEA at low doses of 1.25 and 2.5 mg/kg, i.p., with PMSF had no impact on threshold for electroconvulsions. Similarly, neither PMSF (30 mg/kg) nor ACEA (15 mg/kg) administered alone affected the electroconvulsive threshold in mice. Moreover, ACEA (at a subthreshold dose of 2.5 mg/kg; i.p.) co-administered with PMSF potentiated significantly the antielectroshock activity of valproate by reducing its ED50 from 258.3 to 195.1 mg/kg (P < 0.01). Isobolographic transformation of data revealed that the interactions between valproate and ACEA (at 1.25 and 2.5 mg/kg) combined with PMSF were additive. In the chimney test, the combination of ACEA (2.5 mg/kg) and PMSF (30 mg/kg) had no effect on acute adverse effect of valproate and its TD50 (356.4 mg/kg) did not differ significantly from that for valproate administered alone (TD50 = 404.4 mg/kg). Moreover, none of the examined drugs administered either alone or in combinations produced long-term memory deficits in the step-through passive avoidance task and impaired neuromuscular strength in the grip-strength test in mice. In contrast, ACEA (2.5 mg/kg; i.p.) combined with PMSF (30 mg/kg; i.p.) considerably increased both, the free plasma (by 42%; P < 0.01) and total brain (by 49%; P < 0.001) concentrations of valproate (administered at 195 mg/kg; i.p.) in mice. Hence, the observed interaction between valproate and ACEA with PMSF in the maximal electroshock test was pharmacokinetic in nature. Finally, based on this preclinical study, one can conclude that ACEA — a cannabinoid CB1 receptor agonist co-administered with PMSF pharmacokinetically interacted with valproate and thus, providing the enhancement of the antielectroshock activity of valproate in mice, although, the isobolographically determined interaction between drugs was additive. To elucidate the protective role of cannabinoids in the brain during seizures, more advanced neurochemical studies are required." @default.
• W2018104037 created "2016-06-24" @default.
• W2018104037 creator A5058279581 @default.
• W2018104037 creator A5061048580 @default.
• W2018104037 creator A5064192723 @default.
• W2018104037 creator A5078348855 @default.
• W2018104037 date "2006-10-01" @default.
• W2018104037 modified "2023-10-12" @default.
• W2018104037 title "Arachidonyl-2′-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model" @default.
• W2018104037 cites W1592286181 @default.
• W2018104037 cites W1596256312 @default.
• W2018104037 cites W1670633125 @default.
• W2018104037 cites W1966837740 @default.
• W2018104037 cites W1970391423 @default.
• W2018104037 cites W1970644293 @default.
• W2018104037 cites W1973939262 @default.
• W2018104037 cites W1974809694 @default.
• W2018104037 cites W1978379381 @default.
• W2018104037 cites W1985031395 @default.
• W2018104037 cites W1986995831 @default.
• W2018104037 cites W1987721729 @default.
• W2018104037 cites W1988330508 @default.
• W2018104037 cites W1998141662 @default.
• W2018104037 cites W1998171066 @default.
• W2018104037 cites W2001456048 @default.
• W2018104037 cites W2002892961 @default.
• W2018104037 cites W2002909695 @default.
• W2018104037 cites W2016438709 @default.
• W2018104037 cites W2017455957 @default.
• W2018104037 cites W2018953051 @default.
• W2018104037 cites W2018963113 @default.
• W2018104037 cites W2024554713 @default.
• W2018104037 cites W2025784392 @default.
• W2018104037 cites W2029462182 @default.
• W2018104037 cites W2031325622 @default.
• W2018104037 cites W2039280899 @default.
• W2018104037 cites W2040300337 @default.
• W2018104037 cites W2041103585 @default.
• W2018104037 cites W2051367597 @default.
• W2018104037 cites W2053364708 @default.
• W2018104037 cites W2056188558 @default.
• W2018104037 cites W2077467150 @default.
• W2018104037 cites W2078553244 @default.
• W2018104037 cites W2081506540 @default.
• W2018104037 cites W2085649801 @default.
• W2018104037 cites W2087437186 @default.
• W2018104037 cites W2098783607 @default.
• W2018104037 cites W2099570835 @default.
• W2018104037 cites W2112647660 @default.
• W2018104037 cites W2113011586 @default.
• W2018104037 cites W2114932065 @default.
• W2018104037 cites W2117821503 @default.
• W2018104037 cites W2125832312 @default.
• W2018104037 cites W2126766019 @default.
• W2018104037 cites W2126814491 @default.
• W2018104037 cites W2128138152 @default.
• W2018104037 cites W2133309160 @default.
• W2018104037 cites W2149601015 @default.
• W2018104037 cites W2153392906 @default.
• W2018104037 cites W2165518874 @default.
• W2018104037 cites W2169182197 @default.
• W2018104037 cites W2469061880 @default.
• W2018104037 cites W4249046548 @default.
• W2018104037 cites W4249176094 @default.
• W2018104037 doi "https://doi.org/10.1016/j.ejphar.2006.07.037" @default.
• W2018104037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16930590" @default.
• W2018104037 hasPublicationYear "2006" @default.
• W2018104037 type Work @default.
• W2018104037 sameAs 2018104037 @default.
• W2018104037 citedByCount "58" @default.
• W2018104037 countsByYear W20181040372012 @default.
• W2018104037 countsByYear W20181040372013 @default.
• W2018104037 countsByYear W20181040372014 @default.
• W2018104037 countsByYear W20181040372015 @default.
• W2018104037 countsByYear W20181040372016 @default.
• W2018104037 countsByYear W20181040372017 @default.
• W2018104037 countsByYear W20181040372018 @default.
• W2018104037 countsByYear W20181040372019 @default.
• W2018104037 countsByYear W20181040372020 @default.
• W2018104037 countsByYear W20181040372021 @default.
• W2018104037 countsByYear W20181040372022 @default.
• W2018104037 countsByYear W20181040372023 @default.
• W2018104037 crossrefType "journal-article" @default.
• W2018104037 hasAuthorship W2018104037A5058279581 @default.
• W2018104037 hasAuthorship W2018104037A5061048580 @default.
• W2018104037 hasAuthorship W2018104037A5064192723 @default.
• W2018104037 hasAuthorship W2018104037A5078348855 @default.
• W2018104037 hasConcept C126322002 @default.
• W2018104037 hasConcept C148001335 @default.
• W2018104037 hasConcept C15744967 @default.
• W2018104037 hasConcept C169760540 @default.
• W2018104037 hasConcept C170493617 @default.
• W2018104037 hasConcept C181199279 @default.
• W2018104037 hasConcept C185592680 @default.
• W2018104037 hasConcept C2775858608 @default.
• W2018104037 hasConcept C2777010014 @default.
• W2018104037 hasConcept C2778186239 @default.
• W2018104037 hasConcept C2778938600 @default.

• next